Insulinlike growth factors 1 and 2, and insulinelike growth factor binding proteins 1 and 3 in bone tumors
Abstract
Insulin-like growth factors 1 and 2 (IGF-1 and IGF-2) and insulin-like growth factor binding proteins IGFBP-1, IGFBP-3 were measured by ELISA techniques in blood serum of patients with 113 primary bone tumors. It was found a significant increase of IGF-1, 2 and IGFBP-1, 3 levels in bone tumors, compared to control group; significant increase of IGF-1, 2 levels in malignant bone tumors, compared to benign neoplasms of bones, and significant increase of IGFBP-3 levels in benign neoplasms compared to the malignant bone tumors and control group. Were found a significant differences of levels of these substances, depending on the histological type of cancer.
About the Authors
N. E. Kushlinskii
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Yu. N. Soloviev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
Yu. S. Timofeev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
I. V. Babkina
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
O. I. Kostyleva
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
I. V. Boulytcheva
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
I. N. Kuznetsov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
M. D. Aliev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Russian Federation
Russian Federation
References
1. Clemmons D.R. Value of insulin-likegrowth factor system markers in the assessment of growth hormone status. Endocrinol. Metab. Clin. North. Am. 2007, v. 36, p. 109-129.
2. Frystyk J. Free insulin-like growth factors - Measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm. IGF Res. 2004, v. 14, p. 337-375.
3. George Vardatsikos, Anita Sahu, Ashok K. Srivastava. The Insulin-Like Growth Factor Family: Molecular Mechanisms, Redox Regulation, and Clinical Implications, antioxidants & redoxsignaling. Volume 11, Number 5, 2009, 1165. Mary Ann Liebert, Inc.
4. Dupont J., Pierre A., Froment P., Moreau C. The insulin-like growth factor axis in cell cycle progression. Horm. Metab. Res. 2003, v. 35, p. 740-750.
5. Zhuang D., Ceacareanu A.C., Lin Y. et al. Nitric oxide attenuate sinsulin-or IGF-I-stimulated aortics mooth muscle cell motility by decree sing H2O2 levels: Essential role of cGMP. Am. J. Physiol. Heart Circ. Physiol. 2004, v. 286, p. 2103-2112.
6. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxiainducible factor1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 2002, v. 277, p. 38205-38211.
7. Conover C.A. Insulin-like growth factor-binding proteins and bone metabolism. Am. J. Physiol. Endocrinol. Metab. 2008, v. 294, p. 10-14.
8. Ulaner G.A., Vu T.H., Li T., Hu J.F., Yao X.M., Yang Y. Loss of imprinting of IGF2 and H19 in osteosarcoma is accompanied by reciprocal methylation changes of a CTCF-binding site. Hum. Mol. Genet. 2003, v. 12, p. 535-549.
9. Riggi N., Cironi L., Provero P., Suva M.L., Kaloulis K., Garcia-Echeverria C. Development of Ewing’s sarcoma from primary bone marrow-derived mesenchymal progenitor cells. Cancer Res. 2005, v. 65, p. 11459-11468.
10. Kageyama K., Moriyama T., Hizuka N. et al. Hypoglycemica Associated with Big Insulin-Like Growth Factor II Produced during Developmen of Malignant Gibrous Hisiocytoma. End. J. 2003, v. 50, No. 6, p. 753-758.
11. Rikhof B., de Jong S., Suurmeijer A.J., Meijer C., van der Graaf W.T. The insulin-like growth factor system and sarcomas. J. Pathol. 2009, v. 217, p. 469-482.
12. Samani A.A., Yakar S., Le Roith D., Brodt P. The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights. Endocrine Reviews. 2007, v. 28, No. 1, p. 20-47.
13. Tang Y., Zhang D., Fallavollita L., Brodt P. Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res. 2003, v. 63, p. 1166-1171.
14. Suem Firth, Robertc Baxter. Cellular Actions of the InsulinLike Growth Factor Binding Proteins. Endocrine Reviews. 2002, v. 23, p. 824-854.
Review
For citations:
Kushlinskii N.E., Soloviev Yu.N., Timofeev Yu.S., Babkina I.V., Kostyleva O.I., Boulytcheva I.V., Kuznetsov I.N., Aliev M.D. Insulinlike growth factors 1 and 2, and insulinelike growth factor binding proteins 1 and 3 in bone tumors. Bone and soft tissue sarcomas, tumors of the skin. 2012;(3):53-57. (In Russ.)
Views:
66
Email this article 
